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Context:Transient hypothyroxinemia is common in infants less than
30 wk gestation and is associated with neurodevelopmental deficits.
Reductions in T4 and T3 levels with TSH unchanged are the key
features of severe illness using surrogate indices of overall severity of
illness, but these do not inform the impact of individual disease
conditions or drug use.
Objective: Our objective was to investigate the contribution of post-
natal factors to the variations in serum levels of iodothyronines,
thyroid-binding globulin, and TSH.
Design: We recruited a cohort of infants (23–34 wk gestation; n 
780) between January 1998 and September 2001.
Setting and Patients: The study involved 11 level III Scottish neo-
natal intensive care units and included cohorts of infants delivered at
23–34 wk gestation.
Main Outcome: We assessed serum levels of iodothyronines, thy-
roid-binding globulin, and TSH at 7, 14, and 28 d adjusted for the
potentially significant postnatal influences (n  31).
Results: Serum levels of TSH, free T4, T3, and T4 are variably but
significantly associated with bacteremia, endotracheal bacterial cul-
tures, persistent ductus arteriosus, necrotizing enterocolitis, cerebral
ultrasonography changes, oxygen dependence at 28 d, and the use of
aminophylline, caffeine, dexamethasone, diamorphine, and
dopamine.
Conclusions: There are many more associations of postnatal factors
with transient hypothyroxinemia than had previously been consid-
ered in preterm infants. Alternative strategies should be considered
for correction of hypothyroxinemia rather than sole reliance on the
direct therapy of hormone replacement. A more oblique preventative
approach may be necessary through reduction in the incidence or
severity of individual illness(es). Similarly, alternatives to those
drugs that interfere with the hypothalamic-pituitary-thyroid axis
should be evaluated (e.g. other inotropics instead of dopamine).
(J Clin Endocrinol Metab 90: 5954–5963, 2005)
TRANSIENT HYPOTHYROXINEMIA IS the commonestthyroid dysfunction in preterm infants and is charac-
terized by a temporary postnatal reduction from cord values
in serum levels of T4 and free T4 (FT4) but with normal TSH
levels (1, 2). Transient hypothyroxinemia is present in the
majority of infants less than 30wk gestation and is associated
with neurodevelopmental deficits, characteristically reduc-
tions in intelligence quotient scores (3–6) but also an in-
creased risk of cerebral palsy (5). T4 supplementation in
infants less than 30 wk has shown no overall benefit in
neurodevelopmental outcome but may improve outcome in
infants less than 27wk gestation (7). The etiology of transient
hypothyroxinemia is not clear and may have contributions
from thewithdrawal ofmaternal-placental T4 transfer (8–10),
hypothalamic-pituitary-thyroid immaturity (11, 12), devel-
opmental constraints on the synthesis (13–15) and peripheral
metabolism of iodothyronines (16–18), iodine deficiency (19,
20), and nonthyroidal illness (16, 21–23).
Respiratory distress syndrome is an acute nonthyroidal
illness and the most frequently studied condition over the
past 30 yr to determine whether illness alters serum thyroid
hormone levels in preterm infants (22, 24–31). Respiratory
distress syndrome is characteristicallymost severe in the few
days after birth, and the majority of studies of thyroid hor-
mone status in preterm infants have been limited to the first
week of life (24, 25, 27, 29–31); but the nadir of transient
hypothyroxinemia may extend beyond this early period (e.g.
Ref. 2). In addition to respiratory distress syndrome, preterm
infants can also suffer from a spectrum of illness within, and
outside of, this early phase of postnatal life.
To determine the relationship between critical illness in
preterm infants and thyroid hormone status, we recently
analyzed data from a cohort of preterm infants (23). A range
of serum thyroid hormones wasmeasured over the first 28 d,
and levels were then correlatedwith severity of illness on the
day blood was sampled using a routinely applied scoring
system as a surrogate marker of illness severity. The scoring
system used was that of The British Association of Perinatal
Medicine (BAPM), which was initially devised to quantify
resources required by UK neonatal intensive care units such
as nursing staffing numbers, expertise, and equipment, with
severity of illness being related to the amount of resource
required (32). The application of the BAPM scoring system
allows systematic categorization of a large sample of preterm
infants by a uniform set of parameters describing illness
severity. The key outcomes of our study were that serum
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TSH was unchanged with BAPM score, but there were re-
ductions in serum T4 and T3 in those infants requiring the
maximal level of intensive care (23). However, this approach
categorizes only overall severity of illness but not the impact
of individual disease conditions on iodothyronine levels.
To reveal the relationship between specific illnesses, drug
use, and nutrition on postnatal thyroid hormone status, we
have analyzed data from a cohort of preterm infants born
from 23–34 wk gestation.
Subjects and Methods
Data were collected between January 1998 and September 2001.
This study recruited a cohort of mothers and infants delivered at
23–34wk gestation andwhowere part of amulticenter study of transient
hypothyroxinemia in 11 level III Scottish neonatal intensive care units.
Gestational age of infants was calculated frommenstrual history and, in
most instances, was confirmed by ultrasound examination in the first
trimester. Exclusion criteria from the study were known viral hepatitis
or HIV positivity (or at high risk), major congenital abnormality, or if
mothers were unable to provide informed consent. The study was ap-
proved, as appropriate, by the Multicenter Research Ethics Committee
(Edinburgh) and the Tayside Committee on Medical Research Ethics; in
all cases, written informed consent was obtained.
All infants had intensive care support as required, including inter-
mittent positive pressure ventilation and, where appropriate, correction
of fluid, electrolyte, blood glucose, and acid-base abnormalities. Blood
pressure was supported with inotropes, plasma, or crystalloids as re-
quired. Infants with significant persistence of the ductus arteriosus were
treated with diuretics and indomethacin or surgical ligation if appro-
priate. Parenteral nutrition regimens, if required, were based on a so-
lution of electrolytes, dextrose 10%, amino acids (Vaminolact; Fresenius
Kabi, Cheshire, UK), a phosphate supplement (Addiphos; Fresenius
Kabi), water-soluble vitamins (Solvito N; Fresenius Kabi), and trace
elements (Peditrace; Fresenius Kabi) to levels recommended by the
manufacturer. In tandem, a fat emulsion (Intralipid 20%; Fresenius Kabi)
with added fat-soluble vitamins (Vitlipid; Fresenius Kabi) was used.
Enteral feeds were started when the condition of the infant was stable,
preferably expressed breast milk from the infant’s mother or Cow and
Gate Nutriprem I Low Birthweight Formula (Cow & Gate, Wiltshire,
UK). Thereafter, enteral feed volumes were gradually increased as de-
termined by the infants’ clinical condition, with reciprocal reductions in
the volume of parenteral nutrition infused. Total caloric intakes and the
relative contributions from parenteral and enteral nutrition were cal-
culated at 1, 7, 14, and 28 d.
Blood was collected at postnatal d 7 (n  591), 14 (n  514), and 28
(n  375) from infants of 23–34 wk. The blood samples were allowed to
separate for at least 15 min and then centrifuged at 4000 rpm for 5 min.
If collected outside of normal laboratory hours, the blood was stored at
4 C (maximum, 12 h) before processing. The serumwas removed, stored,
and transported at a maximum of 20 C for assays in one laboratory
(T.J.V.).
Provided sufficient serum was available, T4, FT4, TSH, T3, rT3, T4
sulfate (T4S), and thyroid-binding globulin (TBG) levels were deter-
mined. Serum T4, T3, and rT3 were measured by in-house RIA; FT4 by
Vitros ECI technology (Ortho-Clinical Diagnostics; Amersham, Little
Chalfont, UK); TSH byDynotest immunoradiometric assay; and TBG by
Dynotest RIA (Brahms, Berlin, Germany). T4S was prepared by the
method of Eelkman-Rooda et al. (33). The measurements of T4S in serum
were done by a specific antibody, as described previously (34). Within-
assay coefficients of variation were calculated as 2–8% for T4 (50–147
nmol/liter), 3–7% for FT4 (7.4–27.7 pmol/liter), 2–6% for T3 (0.72–4.24
nmol/liter), 3–4% for rT3 (0.19–0.59 nmol/liter), 6–17% for T4S (46–514
pmol/liter), 2–5% for TSH (0.2–16.6 mU/liter), and 2–4% for TBG (5.9–
38.4mg/liter). Between-assay coefficients of variationwere 5–10% for T4
(49–154 nmol/liter), 5–10% for FT4 (9.0–28.8 pmol/liter), 8% for T3
(0.86–4.54 nmol/liter), 9–16% for rT3 (0.21–0.58 nmol/liter), 4–19% for
T4S (48–501 pmol/liter), 2–14% for TSH (0.1–16.9 mU/liter), and 2–3%
for TBG (6.7–30.1 mg/liter).
Infants were subdivided into gestational age groups (23–27, 28–30,
and 31–34 wk) tomaintain consistencywith previous publications using
this data set.
Infant disorders were recorded as follows: respiratory distress syn-
drome [requiring oxygen with or without ventilatory support, with
severity of illness as mean of first 48 hourly fractional inspired oxygen
(FiO2) measurements]; oxygen dependency at d 28 (28 d was the max-
imum length any one infant was included in our study and is an indi-
cator of evolving chronic lung disease that is likely to have been present
earlier in the neonatal period); cerebral pathology [the sonographic
presence and grade of intraventricular hemorrhage (35) and periven-
tricular leukomalacia]; persistent ductus arteriosus (requiring treatment
with fluid restriction and diuretics with or without indomethacin or
surgery); and necrotizing enterocolitis (requiring treatment with total
parenteral nutrition and antibiotics). Birthweight ratios were calculated
for each infant using reference values obtained from the Scottish Mor-
bidity Record SMR2 as supplied by the Information and Statistics Di-
vision of the Common Services Agency, Edinburgh. Birthweight ratio is
the infant’s birthweight divided by the mean birthweight of all Scottish
infants born between 1987 and 1998,matched for sex and gestational age.
For each infant, the postnatal day of onset, organism, and site(s) of
positive culturewas recorded for each episode of late-onset infection (3
postnatal days). Infections were included if one or more cultures were
positive and if the infantwas treatedwith an antibiotic course. Datawere
not recorded about infants who on clinical suspicion were treated with
an antibiotic course as if infected but culture negative; it is likely that the
number of such infants was small.
A pragmatic hierarchy of positive culture sites was established to
allow grouping of culture-positive, antibiotic-treated infants: 1) blood
(one infant with a positive cerebrospinal fluid as well as a positive blood
culture with the same organism was included in this group), 2) endo-
tracheal tube secretions, 3) vascular access catheter tips, 4) surface in-
cluding oropharyngeal and rectal swab cultures, and 5) urine. Infants
withmore than one site culture positive were assigned to the higher site.
The infants classified within each site of infection were then stratified
according to the range of days of onset of infection (3–8, 10–16, and
24–29 d) and so linked to the thyroid hormone serum sampling days of
7, 14, and 28 postnatal days, respectively. The range of days of onset of
infections was limited to a constant period before each day when blood
was sampled for iodothyronine, TSH, and TBG levels and based on the
assumption thatwith the onset of infection in these periods the attendant
inflammatory response would have the most effect on their levels. If an
infant was infected simultaneously with two or more organisms, then
all were recorded in the data set and analyzed; the combinations of
organisms (with number of episodes in parentheses) were as follows: in
blood, bacteria and fungi (three) and bacteria and bacteria (two); in
endotracheal tube secretions, bacteria and fungi or ureaplasma (three).
For the following drugs (selected on the basis of established or po-
tential hormonal ormetabolic effects on thyroid hormonemetabolism or
inflammatory responses), the postnatal days of prescription of various
drugs was recorded: dexamethasone, phenobarbitone, diamorphine,
morphine, insulin, glucagon, aminophylline, caffeine, dopamine, phe-
nytoin, and indomethacin. Diamorphine and morphine were recorded
separately but subsumed for the analysis; we refer to them hereafter as
diamorphine.
Themain analysis of the datawas performed using univariate general
linear modeling, in three steps. First, we assessed, singly, the impact of
the 31 postnatal factors upon the levels of iodothyronine, TSH, and TBG
on d 7, 14, and 28, as described in the previous paragraphs. Second, the
factors that were significantly associated singly were then entered to-
gether into a model to determine their adjusted impact. If respiratory
distress syndrome and mean FiO2 were both significantly associated in
step one, then only mean FiO2 was entered into the second step. Third,
a final model used only the significant factors (because this minimizes
the loss of data caused by missing information). The iodothyronines,
TSH, and TBG were log transformed for this analysis because the data
were not normally distributed. Linear modelingwas performed for each
day of sera sampling. Respiratory distress, oxygen dependence at d 28,
cranial ultrasound change, persistent ductus arteriosus, and necrotizing
enterocolitis were recorded as present or absent and were not time
specific and were entered into the first step of each regression analysis,
i.e. on d 7, 14, and 28. Drug use was entered as present (or absent) on
d 7, 14, and 28 as appropriate to the model.
The regression analysiswas used to determine the predictedmean for
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each iodothyronine, TBG, or TSH level, at each day of sampling, adjusted
for other factors in the model; the difference was calculated, for each
factor, between the groups geometric mean gestation (irrespective of
gestational group) and predicted mean.
Results
Datawere collected on cord blood (as reported previously)
(36) and on postnatal d 7, 14, and 28. Seven hundred eighty
infantswere included in this data set and subdivided into the
gestational age groups: 23–27, 28–30, and 31–34wk (Table 1).
The most common disorder noted was respiratory distress
syndrome, particularly in the lower gestational groups,
where the other disorders were also more frequent (Table 1).
On postnatal d 7, 14, and 28, data were available for 551,
488, and 355 infants, respectively. The number of descriptors
of clinical disorders available for regressionmodeling varied
on each day of sampling because not all infants had their full
quota of three postnatal sera samples taken (Table 2).
Drug use coinciding with the day of the sera testing was
variable (Table 2). Dexamethasone was used very infre-
quently. Dopamine and indomethacin usewasmoderate and
more frequently administered at d 7 and in the infants born
at a younger gestational age. Diamorphine, aminophylline,
and caffeine were relatively frequently administered with a
bias toward the lower gestational age groups. Total nutri-
tional intakes were significantly lower in the 23- to 27-wk
group compared with other groups at 7 and 14 d (Table 2),
and this pattern was the same for enteral nutrition. Mean
FiO2 was significantly lower in the 31- to 34-wk gestational
group comparedwith the other groups (Table 2). Birthweight
ratiowas significantly lower in the 28- to 30- and 31- to 34-wk
groups compared with the 23- to 27-wk group at d 7 and
more variably at d 14 and 28 (Table 2).
Infection was most common in the 23- to 27-wk group and
most frequent with onset at d 3–8. Blood was the most
common site of infection. Gram-positive cocci, especially
coagulase-negative staphylococci, were the most common
organism in all gestational groups (Table 3).
Data in parentheses in the following paragraphs refer to
the difference between the predicted mean and the group
mean.
T4 levels on d 7 were positively associated with gestation
(11.3 nmol/liter per week of gestation) and aminophylline
use on d 7 (10.86 nmol/liter) and negatively associated
with infection in blood or endotracheal tube (10.40 nmol/
liter), persistent ductus arteriosus (14.07 nmol/liter), and
necrotizing enterocolitis (12.10 nmol/liter). Together, these
factors contribute appreciably (56%) to the variation in T4
levels (Table 4). Three factors associated with T4 levels on d
7 were also significant at d 14: gestation (6.59 nmol/liter),
persistent ductus arteriosus (21.87 nmol/liter), and infec-
tion in blood or endotracheal tube (13.08 nmol/liter) (Table
5). Three other factors became significant by d 14: oxygen
dependence at d 28 (11.36 nmol/liter), diamorphine use on
d 14 (20.33 nmol/liter), and dopamine use on d 14 (39.12
nmol/liter) (Table 5). By d 28, only diamorphine use (45.74
nmol/liter) and gestation (6.73 nmol/liter per week) were
associated with levels of T4 (Table 6).
FT4 levels on d 7 were positively associated with gestation
(1.85 pmol/liter per week) and cranial ultrasound changes
(2.73 pmol/liter) (Table 4). By d 14, gestation was still
associatedwith levels of FT4 (1.26 pmol/liter perweek) and
also dexamethasone (6.25 pmol/liter) (Table 5). At d 28,
gestation FT4 was still positively associated (0.77 pmol/
liter per week), but diamorphine was associated negatively
(3.89 pmol/liter) (Table 6).
TSH levels on d 7, 14, and 28 were negatively associated
with birthweight ratio (1.43, 1.84, and 1.15 mU/liter,
respectively) (Tables 4–6). Caffeine was negatively associ-
ated with TSH at d 7 (0.61 mU/liter) but positively asso-
ciated at d 14 (1.38 mU/liter).
T3 levels at d 7 were positively associated with gestation
(0.16 nmol/liter), total nutrition (0.51 nmol/liter), and
aminophylline use (0.21 nmol/liter); infection in blood or
endotracheal tube on d 3–8 was negatively associated (0.19
nmol/liter) (Table 4). At d 14, gestation remained positively
associated (0.14 nmol/liter); diamorphine was negatively
associated with T3 (0.21 nmol/liter) as were dopamine
(0.57 nmol/liter), dexamethasone (0.82 nmol/liter), in-
fection in blood or endotracheal tube (0.34 nmol/liter),
persistent ductus arteriosus (0.24 nmol/liter), cranial ul-
trasound changes (0.18 nmol/liter), and oxygen depen-
dence at 28 d (0.20 nmol/liter) (Table 5). At d 28, gestation
(0.09 nmol/liter), total nutrition (0.46 nmol/liter), dopa-
mine (0.83 nmol/liter), and diamorphine (-0.96 nmol/liter)
were associated with T3 levels (Table 6).
rT3 levels at d 7 were positively associated with gestation
(0.07 nmol/liter) and negatively associated with birth-
weight ratio (0.42 nmol/liter) and caffeine use (0.20
nmol/liter) (Table 4). By d 14, gestation (0.04 nmol/liter),
FiO2 (0.01 nmol/liter), infection in blood on d 10–15 (0.25
nmol/liter), indomethacin use on d 14 (0.32 nmol/liter),
andmale gender (0.09 nmol/liter) were associatedwith rT3
levels (Table 5). At d 28, necrotizing enterocolitis (0.19
nmol/liter) and total nutrition (0.27 nmol/liter) were as-
sociated with rT3 levels (Table 6).
TBG levels at d 7 were positively associated with gestation
(1.07 mg/liter) and negatively with infection in blood or
endotracheal tube (1.64 mg/liter) (Table 4). At d 14, ges-
tation (0.54mg/liter), dopamine (5.60mg/liter), and dia-
morphine (2.02 mg/liter) were associated with TBG (Table
5). At d 28, birthweight ratio (7.49 mg/liter) and diamor-
phine (4.10 mg/liter) were associated with TBG levels (Ta-
ble 6).
At d 7, T4S levels were associated with gestation (134
pmol/liter), oxygen dependence at 28 d (258 pmol/liter),
FiO2 (9 pmol/liter), and male gender (444 pmol/liter)
(Table 4). At d 14, gestation (86 pmol/liter), FiO2 (6
TABLE 1. Burden of disease (number and percentage) in the
study population
Gestation age grouping
23–27 wk
[n (%)]
28–30 wk
[n (%)]
31–34 wk
[n (%)]
Respiratory distress syndrome 138 (93) 223 (85) 184 (50)
Oxygen dependence at 28 d 100 (67) 72 (28) 11 (3)
Cranial ultrasound change 73 (49) 54 (21) 11 (3)
Persistent ductus arteriosus 68 (46) 36 (14) 8 (2)
Necrotizing enterocolitis 26 (18) 27 (10) 9 (2)
Total numbers per group 149 261 370
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pmol/liter), and infection in blood or endotracheal tube
(293 pmol/liter) were associated (Table 5). By d 28, only
gestation (100 pmol/liter) remained associated with T4S
levels (Table 6).
Discussion
Two early studies of the effect of respiratory distress syn-
drome on serum thyroid hormone levels, which extended the
study period beyond the first week of life, suggested a per-
sistent effect (26, 28); additional reports have not confirmed
these observations (22, 30), including our study where only
marginal associations are present with T4S and rT3 levels.
This lack of association is not surprising given the acute and
time-limited nature of this syndrome to the early neonatal
period and that more recently severity has been attenuated
by the use of prenatal corticosteroids and postnatal surfac-
tant therapies.
In our preterm infants with late-onset infections, there are
associations with marked reductions in T4, T3, and TBG lev-
els. The definition of late-onset blood infection in preterm
infants remains ambiguous and without consensus (37–40).
Our definition was based on the pragmatic clinical definition
used by collaborators in this study. If we were to apply the
most detailed and stringent definitions of late-onset blood
infections to our data, our criteria of one positive blood
culture and the patient treated with a course of antibiotics
would fulfill the National Institute of Child Health and Hu-
man Development (NICHD) Neonatal Research Network
definition of possible infection (40). A definite infection re-
quires two positive blood cultures drawn within 2 d of each
other or one positive blood culture and elevated C-reactive
protein within 2 d of blood culture. Data collection in our
study anteceded publication of NICHD definitions; by com-
parison, our definition has led to dilution of the effect, and
meeting theNICHDcriteria for definite infectionwould have
strengthened the negative associations with thyroid hor-
mone levels.
The predominant organism associated with infection in
our study was coagulase-negative staphylococcus, and this
is consistent with previous reports of infection (37–40) in
extreme preterm infants; its interpretation is notoriously dif-
ficult where sampling is more frequent and where there is a
higher risk of contamination. The novelty of our approach
was the consideration of up to three acquired infections of
late onset. This necessitated a hierarchical approach when
there was concurrent culture of the same organism at dif-
ferent sites. Bacteremia was considered clinically to be the
most important, followed by the endotracheal tube secre-
tions, vascular access catheter tips, and surface infections.
The number of infants who had positive cultures from only
TABLE 3. Organisms by site and grouped by day of onset and gestation
Sitea and organism of infection
Onset of infection 3–8 d Onset of infection 10–15 d Onset of infection 24–28 d
23–27 wk 28–30 wk 31–34 wk 23–27 wk 28–30 wk 31–34 wk 23–27 wk 28–30 wk 31–34 wk
BLOOD
Gram-positive organisms 34 23 8 15 17 6 9 3
Staphylococcus coagulase-negative 32 23 7 14 16 6 8 3
Staphylococcus aureus 1 1 1 1
Enterococcus spp 1 1
Gram-negative organisms 2 1 1 2 1 1
E. coli 1 1
Klebsiella 1 1
Pseudomonas 1
Acinobacter 1 1
Serratia 1
Fungi 1 1 1
Candida albicans 1 1 1
ENDOTRACHEAL TUBE SECRETIONS
Gram-positive organisms 11 3 2 6 1
Staphylococcus coagulase-negative 11 3 2 4
Staphylococcus aureus 2 1
Gram-negative organisms 1 2
E. coli 1
Klebsiella 1
Enterobacter 1
Fungi 2
Candida albicans 2
Other 3 1 1
Mycoplasma hominis 1
Ureaplasma urealyticum 2 1 1
VASCULAR ACCESS CATHETER TIP
Gram-positive organisms 1 1
Staphylococcus coagulase-negative 1 1
SURFACEb
Gram-positive organisms 2
Staphylococcus aureus 2
Maximum n 101 198 252 101 190 197 97 155 103
a No urinary tract infections occurred within the days of onset used in this table.
b Including oropharyngeal and rectal swabs.
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vascular access catheter tips, surface swabs, or urine andwho
were treated with antibiotics was few. This approach nu-
merically weights the importance of bacteremia and con-
versely underrecognizes the contribution of similar organ-
isms particularly in the endotracheal tube secretions. Despite
this, we find strong and persistent associations between re-
duced levels of T4 and T3 on postnatal d 7 and 14 and co-
agulase-negative staphylococcal infection in endotracheal
tube secretions. In extreme preterm infants, the local proin-
flammatory cytokine response to endotracheal colonization
immediately after birth is highest in neonates colonized with
a Gram-negative pathogen, but this response is also associ-
ated with infection with coagulase-negative staphylococci
(41). The mortality associated with Gram-negative bacteria
and fungal sepsis is verymuch higher (up to 4-fold) than that
reported for coagulase-negative staphylococcus (38–40). We
are unable to comment on the relationship between Gram-
negative bacteria and fungal sepsis and iodothyronine levels
because these infections were relatively uncommon. Because
the proinflammatory cytokine response is relatively less in
infants with coagulase-negative staphylococci, it is also
highly probable that the thyroid hormone responses to sepsis
with these organisms are also similarly attenuated.
Serum T3 and FT4 levels are reduced in adults with sub-
arachnoid hemorrhage (42, 43). In very low birthweight in-
fants, low serum T4 levels during the first week of life are
associated with intraventricular hemorrhage but not there-
after at 2–4wk postnatal age (44, 45). In such low birthweight
infants, low serum T4 and TSH levels measured within 6 h
after birth are associated with severe intraventricular hem-
orrhage and death (46). These studies emphasize the limited
temporal effect of intraventricular hemorrhage on T4 levels
to the early postnatal period; this may be the reason for
limited associations in our results.
In respiratory distress syndrome (47), sepsis (48), intra-
cranial hemorrhage (49), and necrotizing enterocolitis (48),
the effects on serum thyroid hormone levels are likely to be
mediated in part through the acute inflammatory cytokine
response (50). There is no direct evidence for this cytokine
response in preterm infants with a persistent ductus arteri-
osus, but reduced plasma T3 levels is a feature of cardiac
failure in adults (51).
Aminophylline and caffeine are used as respiratory stim-
ulants in preterm infants with recurrent apnea. Both anterior
pituitary and thyroid cells have cAMP-dependent regulation
of gene expression and are potential sites for theophylline
(the active metabolite of aminophylline and caffeine), which
acts as a phosphodiesterase inhibitor and so influences thy-
roid hormone metabolism. Elevation of pituitary intracellu-
lar cAMP levels increases the expression of the TSH - and
TABLE 4. Significant factors that influence levels of d-7 sera iodothyronines, TSH, and TBG
Variable B SE Anti-log B(effect size)
Group geometric mean
at 30 wk gestation
Change in
predicted mean
t
statistic
P
value
T4 (nmol/liter)
Intercept 0.416 0.092 2.606 90.95 nmol/liter
Gestation 0.051 0.003 1.125 102.28 17.367 0.001
Infection in blood or endotracheal tube on d 3–8 0.053 0.021 0.885 80.55 2.579 0.010
Persistent ductus arteriosus 0.073 0.021 0.845 76.88 3.498 0.001
Necrotizing enterocolitis 0.062 0.023 0.867 78.85 2.695 0.007
Aminophylline d 7 0.049 0.018 1.119 101.81 2.664 0.008
FT4 (pmol/liter)
Intercept 0.440 0.075 2.754 24.99 pmol/liter
Cranial ultrasound change 0.045 0.017 1.109 27.72 2.720 0.007
Gestation 0.031 0.002 1.074 26.84 12.527 0.001
TSH (mU/liter)
Intercept 0.681 0.085 4.797 3.52 mU/liter
Caffeine d 7 0.086 0.035 0.820 2.89 2.455 0.014
Birthweight ratio 0.231 0.086 0.587 2.07 2.684 0.008
T3 (nmol/liter)
Intercept 2.196 0.113 0.006 0.99 nmol/liter
Infection in blood or endotracheal tube on d 3–8 0.093 0.026 0.807 0.80 3.665 0.001
Aminophylline d 7 0.082 0.023 1.208 1.20 3.501 0.001
Total nutrition d 7 0.181 0.041 1.517 1.50 4.439 0.001
Gestation 0.065 0.004 1.161 1.15 16.823 0.001
rT3 (nmol/liter)
Intercept 0.198 0.113 0.634 1.76 nmol/liter
Caffeine d 7 0.052 0.018 0.887 1.56 2.904 0.004
Birthweight ratio 0.118 0.045 0.762 1.34 2.645 0.006
Gestation 0.017 0.003 1.040 1.83 5.154 0.001
TBG (mg/liter)
Intercept 0.670 0.060 4.677 20.6 mg/liter
Gestation 0.022 0.002 1.052 21.67 11.053 0.001
Infection in blood or endotracheal tube on d 3–8 0.036 0.015 0.920 18.96 2.357 0.019
T4S (pmol/liter)
Intercept 4.102 0.149 12647.4 1881.3 pmol/liter
Infant gender 0.092 0.020 1.236 2325.2 4.569 0.001
Oxygen dependence d 28 0.064 0.031 0.863 1623.6 2.086 0.038
Gestation 0.032 0.005 0.929 1747.7 6.809 0.001
FiO2 mean 0.002 0.001 1.005 1890.0 2.307 0.022
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-subunit genes (52). Many of the effects of TSH activation
of the thyroid gland are mediated through stimulation of the
adenyl cyclase cascade regulating the expression of many
genes including TSH receptor and thyroglobulin (53).
In the majority of adults and children, the result of ther-
apeutic doses of theophylline is to increase plasma T4 levels
with variable increases in rT3 and T3 (54). A single dose of iv
aminophylline to adult asthmatics is followed by acute in-
creases in TSH and T4 (55), whereas effects are absent after
chronic administration (2 wk) to infants (56). The effect of
caffeine on neonatal thyroid hormones is unknown. In our
study, there is a dichotomy of effect of caffeine on TSH at d
7 and 14. Aminophylline is associated with increases of T4
and T3 levels on d 7, whichmay reflect recent administration.
High-dose glucocorticoids have multiple effects on the
thyroid axis, including inhibition of TSH secretion (57), de-
creases in extrathyroidal conversions of T4 to T3 (58, 59),
reductions in serum TBG levels (60), and an increase in renal
clearance of iodine (61). Postnatal dexamethasone has been
used variously in preterm infants to accelerate fetal lung
maturity and for the prevention or therapy of chronic lung
disease; follow-up studies on such infants have shown sub-
stantial adverse effects on neuromotor and cognitive func-
tion (e.g. Refs. 62 and 63). Dexamethasone use is confined to
our extreme preterm infants who are not only the highest-
risk group for transient hypothyroxinemia (15, 21, 22) but
also for a less favorable neurodevelopmental outcome (e.g.
64). Maintaining serum FT4 levels in extreme preterm infants
may be a priority for sustaining postnatal brain development
(65). In our infants, postnatal dexamethasone use is associ-
atedwith a substantial reduction in serumFT4 levels, and this
may also contribute, in addition to a direct effect of dexa-
methasone (66), to the unfavorable neurodevelopmental
outcome.
Dopamine infusions are administered to infants for ino-
tropic support and for optimization of renal and splanchnic
perfusion (67). In humans, dopamine has a physiological
inhibitory role in the control of TSH release (68) and thera-
peutic infusions are associated with rapid reductions in se-
rum TSH levels in adults as well as infants and children (69,
TABLE 5. Significant factors that influence levels of d-14 sera iodothyronines, TSH, and TBG
Variable B SE Anti-log B(effect size)
Group geometric mean
at 30 wk gestation
Change in
predicted mean
t
statistic
P
value
T4 (nmol/liter)
Intercept 1.107 0.117 12.794 95.46 nmol/liter
Oxygen dependence d 28 0.055 0.022 0.881 84.10 2.515 0.012
Persistent ductus arteriosus 0.113 0.023 0.771 73.59 4.919 0.001
Infection in blood or endotracheal tube d 10–15 0.064 0.027 0.863 82.38 2.381 0.018
Diamorphine d 14 0.104 0.029 0.787 75.13 3.554 0.001
Dopamine d 14 0.229 0.056 0.590 56.34 4.090 0.001
Gestation 0.029 0.004 1.069 102.05 7.825 0.001
FT4 (pmol/liter)
Intercept 0.644 0.059 4.498 23.24 pmol/liter
Dexamethasone d 14 0.136 0.047 0.730 16.99 2.916 0.004
Gestation 0.023 0.002 1.054 24.50 11.807 0.001
TSH (mU/liter)
Intercept 0.676 0.087 4.742 4.0 mU/liter
Caffeine d 14 0.129 0.034 1.346 5.38 3.838 0.001
Birthweight ratio 0.268 0.087 0.540 2.16 3.095 0.002
T3 (nmol/liter)
Intercept 1.202 0.145 0.063 1.28 nmol/liter
Oxygen dependence d 28 0.074 0.026 0.843 1.08 2.848 0.005
Cranial ultrasound change 0.067 0.026 0.857 1.10 2.599 0.010
Persistent ductus arteriosus 0.092 0.028 0.809 1.04 3.234 0.001
Infection in blood or endotracheal tube on d 10–15 0.133 0.033 0.736 0.94 4.058 0.001
Dexamethasone d 14 0.443 0.088 0.361 0.46 5.021 0.001
Dopamine d 14 0.253 0.067 0.559 0.71 3.772 0.001
Diamorphine d 14 0.076 0.037 0.840 1.07 2.050 0.041
Gestation 0.044 0.005 1.107 1.42 9.462 0.001
rT3 (nmol/liter)
Intercept 0.369 0.085 0.428 1.28 nmol/liter
Infection in blood on d 10–15 0.078 0.024 1.197 1.53 3.202 0.001
Infant gender 0.032 0.013 0.929 1.19 2.412 0.016
Indomethacin d 14 0.098 0.041 1.253 1.60 2.395 0.017
Gestation 0.012 0.003 1.028 1.32 4.687 0.001
FiO2 mean 0.002 0.001 1.005 1.29 3.611 0.001
TBG (mg/liter)
Intercept 0.984 0.068 9.638 20.95 mg/liter
Diamorphine d 14 0.044 0.021 0.904 18.93 2.126 0.034
Dopamine d 14 0.135 0.043 0.733 15.35 3.132 0.002
Gestation 0.011 0.002 1.026 21.49 5.088 0.001
T4S (pmol/liter)
Intercept 4.135 0.160 13645.83 853.3 pmol/liter
Infection in blood or endotracheal tube on d 10–15 0.128 0.042 1.343 1145.8 3.071 0.002
Gestation 0.046 0.005 0.900 767.6 8.707 0.001
FiO2 mean 0.003 0.001 1.007 859.2 2.762 0.006
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70). In addition, dopamine may also have peripheral effects
such as the inhibition of TSH-stimulated T4 release from the
thyroid (71) or alterations in hepatic T4 to T3 conversion (72).
Prolonged use of dopamine even on low infusion rates may
result in reduced T4 and T3 levels and in adults may induce
or exacerbate the changes in serum thyroid hormones asso-
ciated with nonthyroidal illness (73, 74). In very low birth-
weight infants (32 wk gestation, 1500 g birthweight),
dopamine is associated with reductions in serum TSH levels
but also with a relatively greater decline in serum T4 levels
(75). In our study, there was no association of dopaminewith
serum TSH levels but instead with reduced T3 and T4 levels,
a similar pattern to our infant groups previously described
with the severest nonthyroidal illness (23). In our infants,
dopamine is associated with a reduced serum TBG level; this
is a novel finding, and this association has not been reported
before. A previous analysis of this data set, using the BAPM
score as a surrogate marker of illness severity (32), showed
no differences in serum TBG levels between infant groups
with variable illness severity (23). The reduction in TBG
levels associated with dopamine use may also contribute to
the decreased serum T3 and T4 levels.
Morphine suppresses TSH release (76, 77), but to our
knowledge effects on other aspects of thyroid hormone me-
tabolism have not been reported. The association of diamor-
phine use with marked reductions in serum levels of T4, T3,
FT4, and TBG is therefore surprising. It is possible that this
is a spurious observation and diamorphine use is a surrogate
for severity of illness, but this could also be said of the
associations of dexamethasone or dopamine, where there is
already substantive supportive experimental evidence for
their direct effect on thyroid hormone metabolism.
Diamorphine is frequently prescribed in the early neonatal
period, and the lack of association with d-7 T4 levels was not
immediately clear given the significant associations between
its use and T4 levels on postnatal d 14 and 28. However, we
believe that the association at d 7 is obscured by the relative
dominance of the illness prevalent at this time; this mecha-
nism may explain the lack of expected temporal associations
between drugs and specific iodothyronine levels or between
illnesses and specific iodothyronine levels.
Transient hypothyroxinemia in preterm infants is associ-
ated with reductions in developmental quotients and an
increased risk of cerebral palsy. The role of thyroid hormone
status as a contributory factor to cognitive and motor dis-
ability remains unclear, andwe are still left with the question
of whether low serum T4 levels, particularly those associated
with severe illness in preterm infants, are causative per se of
later neurodevelopmental deficits or simply an epiphenom-
enon of illness? This critical question remains unanswered
for the present; because the causative factors for disability
may be multiple and influence each other, it is possible that
hypothyroxinemia and other pathophysiological changes of
illness(es) are interactive in their contributions to cerebral
damage. Our study establishes for the first time that there are
more associations of particular illnesses (or drug uses) with
low serum T4 levels than had previously been considered in
preterm infants. This etiological complexity of low serum T4
levels highlights that consideration should be given to al-
ternative strategies for correction of hypothyroxinemia
TABLE 6. Significant factors that influence levels of d-28 sera iodothyronines, TSH, and TBG
Variable B SE Anti-log B(effect size)
Group geometric mean
at 29 wk gestation
Change in
predicted mean
t
statistic
P
value
T4 (nmol/liter)
Intercept 1.075 0.108 11.885 94.13 nmol/liter
Diamorphine d 28 0.289 0.051 0.514 48.39 5.634 0.001
Gestation 0.030 0.004 1.072 100.86 8.248 0.001
FT4 (pmol/liter)
Intercept 0.855 0.071 7.161 20.58 pmol/liter
Diamorphine d 28 0.091 0.033 0.811 16.69 2.754 0.006
Gestation 0.016 0.002 1.038 21.35 6.701 0.001
TSH (mU/liter)
Intercept 0.668 0.096 4.656 2.98 mU/liter
Birthweight ratio 0.234 0.096 0.584 1.74 2.424 0.016
T3 (nmol/liter)
Intercept 1.188 0.159 0.048 1.31 nmol/liter
Diamorphine d 28 0.575 0.071 0.423 0.35 8.122 0.001
Dopamine d 28 0.440 0.172 0.286 0.48 2.562 0.011
Gestation 0.040 0.006 1.099 1.44 7.124 0.001
Total nutrition d 28 0.131 0.054 1.005 1.77 2.410 0.017
rT3 (nmol/liter)
Intercept 0.186 0.052 1.535 0.95 nmol/liter
Necrotizing enterocolitis 0.080 0.029 1.202 1.14 2.813 0.005
Total nutrition d 28 0.146 0.041 0.998 0.68 3.537 0.001
TBG (mg/liter)
Intercept 1.212 0.034 16.293 21.46 mg/liter
Diamorphine d 28 0.092 0.033 0.809 17.36 2.773 0.006
Birthweight ratio 0.130 0.034 1.349 28.95 3.846 0.001
T4S (pmol/liter)
Intercept 4.891 0.183 77803.66 668.7 pmol/liter
Gestation 0.070 0.006 0.851 569.16 11.282 0.001
To convert T3 and rT3 to ng/dl, multiply by 65.1; T4 to g/dl, multiply by 0.0777; FT4 to ng/dl, multiply by 0.0777; T4S to ng/dl, multiply by
0.085.
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rather than sole reliance on the direct therapy of hormone
replacement. A more oblique preventative approach may be
necessary, for example through reduction in the incidence or
severity of individual illness(es) that influence thyroid hor-
mone levels in these infants; this has probably already oc-
curred for respiratory distress syndrome.
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